Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Weigao Group Medical Polymer Co ( (HK:1066) ) has provided an update.
Shandong Weigao Group Medical Polymer Company Limited has received a filing notice from the China Securities Regulatory Commission approving its plan for H share full circulation. The approval covers the conversion of 48,300,000 previously unlisted shares, representing about 1.06% of its issued share capital, into H shares that will be eligible for listing and trading on the Main Board of the Hong Kong Stock Exchange.
The filing is valid for 12 months from 26 March 2026, during which the company will seek listing and dealing approval from the Hong Kong Stock Exchange for the new H shares. The move is expected to enhance the liquidity of the company’s shares, broaden its investor base, and further integrate its shareholder structure with the international capital market.
The most recent analyst rating on (HK:1066) stock is a Buy with a HK$6.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
More about Shandong Weigao Group Medical Polymer Co
Shandong Weigao Group Medical Polymer Company Limited is a PRC-incorporated medical device manufacturer focused on medical polymer products and related consumables. The company serves hospital and healthcare markets and is listed in Hong Kong, accessing international capital through its H shares on the Main Board of the Stock Exchange of Hong Kong.
Average Trading Volume: 17,919,158
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.96B
See more insights into 1066 stock on TipRanks’ Stock Analysis page.